特一藥業(002728.SZ):海南海力製藥持有腦樂靜膠囊的藥品批件,用於精神憂鬱,煩躁失眠;目前暫未生產
格隆匯8月9日丨有投資者向特一藥業(002728.SZ)提問,“生產抗抑鬱藥的華森製藥,業績3000萬,估值70多億,公司也擁有生產抗抑鬱藥,請問公司抗抑鬱藥的藥效如何?是否可以量產呢?”
特一藥業回覆稱,公司子公司海南海力製藥持有腦樂靜膠囊的藥品批件,功能主治為養心,安神。用於精神憂鬱,煩躁失眠。目前暫未生產。後續,如市場對藥品有急切需求,公司可調整生產安排,對相關藥品進行生產銷售,以滿足市場需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.